Trial Profile
A phase II multicenter, double-blind, placebo-controlled, trial of VLTS-589 [del-1 gene therapy] in subjects with intermittent claudication secondary to peripheral arterial disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2010
Price :
$35
*
At a glance
- Drugs Del-1 gene therapy (Primary)
- Indications Intermittent claudication
- Focus Therapeutic Use
- Sponsors Urigen Pharmaceuticals
- 02 Feb 2006 New trial record.